BRPI0509582A - compostos de tiazol-amina e respectivas composições farmacêuticas - Google Patents

compostos de tiazol-amina e respectivas composições farmacêuticas

Info

Publication number
BRPI0509582A
BRPI0509582A BRPI0509582-4A BRPI0509582A BRPI0509582A BR PI0509582 A BRPI0509582 A BR PI0509582A BR PI0509582 A BRPI0509582 A BR PI0509582A BR PI0509582 A BRPI0509582 A BR PI0509582A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
thiazol
amine compounds
compounds
formula
Prior art date
Application number
BRPI0509582-4A
Other languages
English (en)
Inventor
Yuhpyng L Chen
Lei Zhang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0509582A publication Critical patent/BRPI0509582A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

COMPOSTOS DE TIAZOL-AMINA E RESPECTIVAS COMPOSIçõES FARMACêUTICAS. A presente invenção refere-se aos compostos da Fórmula <124> em que R¬ 1¬, R¬ 3¬, R¬ 4¬, R¬ 5¬, R¬ 6¬ e R¬ 7¬ são como definidos. Compostos da Fórmula <124> têm atividade de inibição da produção de peptídeo A<225>. A invenção também refere-se às composições farmacêuticas e métodos de tratamento de distúrbios e doenças, por exemplo, distúrbios neurodegenerativos e/ou neurológicos, por exemplo, Doença de Alzheimer, em um mamífero compreendendo compostos da Fórmula <124>.
BRPI0509582-4A 2004-04-01 2005-03-23 compostos de tiazol-amina e respectivas composições farmacêuticas BRPI0509582A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55890204P 2004-04-01 2004-04-01
PCT/IB2005/000825 WO2005095367A1 (en) 2004-04-01 2005-03-23 Thiazole-amine compounds for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BRPI0509582A true BRPI0509582A (pt) 2007-10-09

Family

ID=34962046

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509582-4A BRPI0509582A (pt) 2004-04-01 2005-03-23 compostos de tiazol-amina e respectivas composições farmacêuticas

Country Status (6)

Country Link
US (2) US7384968B2 (pt)
EP (1) EP1735292A1 (pt)
JP (1) JP2007530662A (pt)
BR (1) BRPI0509582A (pt)
CA (1) CA2562123A1 (pt)
WO (1) WO2005095367A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1730119T3 (da) 2004-03-23 2008-08-11 Pfizer Prod Inc Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
AU2006293619A1 (en) * 2005-09-22 2007-03-29 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
EP2042172A1 (en) * 2007-09-26 2009-04-01 Inserm Use of tocopherol derivatives as inhibitors of the notch signalling pathway
MX388990B (es) 2011-08-17 2025-03-20 Univ Texas Método de producción de niveles fisiológicos y terapéuticos de óxido nítrico por medio de un sistema de suministro oral.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1168432B (de) 1961-10-25 1964-04-23 Hoechst Ag Verfahren zur Herstellung von N-substituierten 2-Nitro-1-aminoarylverbindungen
JPS5516147B2 (pt) 1971-12-24 1980-04-30
US4217355A (en) 1978-04-24 1980-08-12 Pfizer Inc. Amide therapeutic agents
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
EP1169038B9 (en) * 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
WO2002067918A1 (en) * 2001-02-27 2002-09-06 Banyu Pharmaceutical Co., Ltd. Novel diallylmethylamine derivative
JP2003064064A (ja) * 2001-08-29 2003-03-05 Tokuyama Corp アミドチアゾール誘導体エステル化合物の製造方法
FR2842523A1 (fr) 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
JP2006504796A (ja) 2002-10-09 2006-02-09 ファイザー・プロダクツ・インク 神経変性性障害を処置するためのチアゾール化合物
ZA200602755B (en) 2003-09-06 2007-06-27 Vertex Pharma Modulators of ATP-binding cassette transporters

Also Published As

Publication number Publication date
US20080207712A1 (en) 2008-08-28
US20060084689A1 (en) 2006-04-20
US7384968B2 (en) 2008-06-10
WO2005095367A1 (en) 2005-10-13
EP1735292A1 (en) 2006-12-27
CA2562123A1 (en) 2005-10-13
JP2007530662A (ja) 2007-11-01

Similar Documents

Publication Publication Date Title
BRPI0509069A (pt) compostos de imidazol para o tratamento de distúrbios neurodegenerativos
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BRPI0413709A (pt) compostos para o tratamento de distúrbios neurodegenerativos
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
BRPI0409721A (pt) compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos
WO2007109107A3 (en) Atf4 as a therapeutic target in alzheimers disease and other neurological disorders
BRPI0509504A (pt) compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
CR9815A (es) Compuestos de imidazol para el tratamiento de transtornos neurologicos
BRPI0509582A (pt) compostos de tiazol-amina e respectivas composições farmacêuticas
BRPI0509559A (pt) compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos
BRPI0509464A (pt) compostos tiazol sulfonamida para o tratamento de distúrbios neurodegenerativos
BRPI0513647A (pt) derivados de ácidos 1-fenilalcanocarboxìlicos para o tratamento de doenças neurodegenerativas
BRPI0509386A (pt) compostos de isoxazol- e isotiazol-amina para o tratamento de distúrbios neurodegenerativos
WO2011015646A3 (en) Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
DOP2006000200A (es) Compuestos de imidazol para el tratamiento de trastonos neurologicos
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos
CU23591B7 (es) Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos
MY145068A (en) Imidazole compounds for the treatment of neurodegenerative disorders
DOP2004000970A (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2137 DE 20/12/2011.